Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended ...

Four months ago, Rigel Pharmaceuticals spent just $2 million—plus ponying up another $233 million in potential milestones—to acquire Forma Therapeutics’ leukemia drug Rezlidhia. On Thursday, Rigel got ...

Rigel Pharmaceuticals (NASDAQ:RIGL) detailed record commercial performance for the fourth quarter and full year 2025, while outlining plans to pursue additional in-licensing opportunities and advance ...

Return on Assets (ROA): Rigel Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 12.42%, the company showcases ...

Rigel Pharmaceuticals is back in focus as analysts update their narrative around the stock, with the fair value price target holding steady at $51.6. Supportive voices point to this unchanged figure ...

Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...

CEO Raul Rodriguez highlighted "year-over-year net product sales growth of 68%" and total revenue of $53.3 million for Q1 2025. He noted that Rigel achieved $11.4 million in net income for the quarter ...

Rigel Pharmaceuticals (RIGL) stock hits a 4-month low as 2026 revenue guidance signals a topline contract due to falling contract revenue. Read more here.

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) shares are on the move Wednesday after the company reported fourth-quarter results well above analyst expectations. What Happened: Rigel reported fourth-quarter ...

Shares of Rigel Pharmaceuticals Inc. soared 39.5% in premarket trading Friday, after the biotechnology company announced Food and Drug Administration approval of its Rezlidhia leukemia treatment. With ...